A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms TASUKI-52
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 07 Dec 2023 Status changed from active, no longer recruiting to completed.
- 28 Jun 2022 Planned End Date changed from 31 May 2024 to 1 May 2024.
- 28 Jun 2022 Planned End Date changed from 1 Jul 2022 to 31 May 2024.